drugset / Trial / NCT03837561
The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To Confirm the non-inferiority of CUNOX® to BOTOX® in the glabellar line improvement of moderate to severe glabellar lines.
Timeline
- Start
- 2018-12-13
- Primary completion
- 2019-03-12
- Completion
- 2019-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 20 iu | — |
| Subject | Cunox | Unknown | 20 iu | — |
Indications
No indication recorded.